Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Eli Lilly

An unusually lenient FDA is a knife that cuts both ways for Biogen.

Is Eli Lilly a Better Alzheimer's Stock Than Biogen?

Biogen's Alzheimer's drug approval creates major controversy. Effects of this approval on other companies and the Alzheimer's drug market are discussed.

Biogen Controversy And The Spillover Effect: Actionable Insights

Amgen

BioNTech SE

Moderna

Intellia Therapeutics

Regeneron Pharmaceuticals

Repligen

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

3 Biotech Stocks Poised to Gain in the Second Half of 2021

Netflix

Tesla

Who's right: the bulls or the bears? You'll need to make the final call.

Wall Street Is Completely Clueless About These 3 Popular Stocks

A nonprofit group doesn't like a recent move by Biogen.

How Biogen Made an Enemy of 1 of the Biggest Supporters of Its Alzheimer's Disease Drug

These drug stocks are in competition with Biogen for an Alzheimer's treatment, and can break out in a similar fashion offering better value. The post 3 Better Alzheimer's Drug Stocks to Buy Instead of Biogen appeared first on InvestorPlace.

3 Better Alzheimer's Drug Stocks to Buy Instead of Biogen

The stock price of Biogen has seen a 10% drop over the last five trading days. BIIB stock has seen a massive rally from levels of $267 in early June to around $380 last week, before dropping to $348 currently.

What's Next For Biogen Stock After A 10% Fall Last Week Amid Recent Controversy?

Enel X Collaborates With Biogen To Electrify Take-home Vehicle Fleet In North America

Could Biogen's Big Win With Aduhelm Become a Big Liability?

The drugmaker has had one big clinical setback and another less serious disappointment in recent weeks.

How Bad Is Biogen's Latest Bad News?

The recent approval of Biogen Inc's (NASDAQ: BIIB) high-price Alzheimer's drug is raising questions about who will have access to the $56,000/year treatment that could cost Medicare billions of dollars in coming years. Medicare typically pays unconditionally for approved medicines, but to limit the financial hit from Aduhelm, however, Medicare could restrict access, the Wall Street Journal reported.

Biogen's Costly Alzheimer's Treatment May Face Restricted Medicare Access: WSJ

BIIB stock was boosted when its Alzheimer's drug was approved. The company's strong financials can sustain the stock's growth.

New Alzheimer's Treatment Is A Huge Catalyst for Biogen

It's hard to believe how large Biogen's market opportunity is, now that the FDA has approved its Alzheimer's drug.

The Upside for Biogen Is Absolutely Wild

Many doctors don't like the drug, and the trial data was underwhelming. Nonetheless, Biogen's Alzheimer's drug was approved-- and the market opportunity is huge.

Why Biogen's FDA Approval Is Shocking

Among the stocks in Warren Buffet's Berkshire Hathaway Inc. (NYSE: BRK-B) portfolio, Thursday's biggest loser was Biogen.

How Will the Drop in Biogen's Share Price Hit Buffett's Portfolio?

INCHEON, Korea and CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for BYOOVIZ™, a biosimilar candidate referencing Lucentis®1 (ranibizumab), also known as SB11. Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular disorders, which are a leading cause of blindness. BYOOVIZ has been recommended for approval for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular odemea secondary to retinal vein occlusion (branch RVO or central RVO) and visual impairment due to choroidal neovascularization (CNV) in the European Union (EU).

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™

The surprise approval of Aduhelm provided a big financial boost to Biogen. The biopharma spent the last few years repurchasing billions worth of stock on the dips and has a $4 billion authorization remaining.

Biogen: Score A Big Win For Buybacks

AvalonBay Communities

Blackbaud

Federal Realty Investment Trust

As of Wednesday, the Historical Low Price-Sales model portfolio has returned approximately 16.13% since the Jan. 1 rebalance date and over 244% since the model portfolio's inception in 2010 according to the GuruFocus Model Portfolios page. The top-performing stocks are Biogen Inc. ( BIIB , Financial), CI Financial Group ( CIXX , Financial), Federal Realty Investment Trust ( FRT , Financial), Blackbaud Inc. ( BLKB , Financial) and AvalonBay Communities Inc. ( AVB , Financial).

Top-Performing Stocks in Historical Low Price-Sales Portfolio as of June

Shares of Biogen Inc. were up 0.8% in premarket trading on Wednesday after the company and Eisai Inc. said they plan to speed up the completion of what is called a "confirmatory" clinical trial for its recently approved Alzheimer's disease treatment. In the weeks since the drug's approval in the U.S., Aduhelm has faced criticism over how it was priced and whether or not the clinical data were strong enough to support the approval.

Biogen now says it plans to complete 'confirmatory' study for Alzheimer's drug earlier than required

The U.S. Food and Drug Administration approved the first new Alzheimer's drug in decades over the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.

The Wall Street Journal: FDA approved Biogen Alzheimer's drug despite some objections by staff

Here's one longtime healthcare expert's perspective.

Why Biogen Isn't a Buy After Its Alzheimer's Drug Approval

BioMarin Pharmaceutical

Ultragenyx Pharmaceutical

Roche Holding AG

FDA approval of Biogen's Aduhelm for Alzheimer's should be broadly supportive of biotechnology and pharmaceutical stocks as it signals the agency is willing to be flexible to make important drugs. The rerating of Biogen shares following the FDA decision demonstrates the potential of innovation in the biopharmaceutical industry to generate significant alpha for investors.

Alzheimer's Approval Validates Biopharmaceutical Innovation

Beyond its lofty price tag, there are other impediments to big sales of aducanamab that the market largely ignored this week.

3 More Reasons Biogen's Alzheimer's Drug Will Underperform Wall Street Expectations

One of these agreements could be more important than the other.

Biogen's Alzheimer's Drug Deals With CVS and Cigna: What Investors Should Know

Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.

News for Biogen Stock (BIIB)